eligibility_summary
Eligible: adults 18–70 with diagnosed refractory/relapsed multiple myeloma, survival >12 wks, KPS >50%, ALT/AST <3× ULN, bilirubin <2.0 mg/dL, no serious cardiac/hepatic/renal disease, relapse/non‑remission after HSCT/cell therapy or transplant‑ineligible, suitable for leukapheresis, consent. Exclude: pregnancy, HIV/TB, active HBV/HCV, poor cell transfection/expansion, unstable vitals, psychiatric disorder, severe allergy (IL‑2), serious infection, severe autoimmune, per physician.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: NKG2D Chimeric Antigen Receptor NK Cell Injection (KN1102), a gene‑modified cellular immunotherapy (CAR‑NK). Dosing: three infusions (day 0, 7, 14) at 6×10^8, 1×10^9, or 1.5×10^9 cells. Mechanism: NK cells are engineered with an NKG2D‑based CAR that binds NKG2D ligands on tumor cells, triggering NK activation and cytotoxicity (perforin/granzyme and cytokine‑mediated killing). Compared with CAR‑T, CAR‑NK aims for lower cytokine release risk and multi‑modal killing. Targets: Relapsed/refractory multiple myeloma cells expressing NKG2D ligands (MICA, MICB, ULBP family). Primary pathway engaged: NKG2D–NKG2DL axis on malignant plasma cells, leading to innate immune activation and tumor cell lysis. Study: Early Phase 1, safety/efficacy, single‑center (China).